AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-04-26 |
2024-03 |
2.26 |
2.31 |
0.05 |
2.21% |
2024-02-02 |
2023-12 |
2.76 |
2.79 |
0.03 |
1.09% |
2023-10-27 |
2023-09 |
2.86 |
2.95 |
0.09 |
3.15% |
2023-07-27 |
2023-06 |
2.79 |
2.91 |
0.12 |
4.30% |
2023-04-27 |
2023-03 |
2.44 |
2.46 |
0.02 |
0.82% |
2023-02-09 |
2022-12 |
3.54 |
3.6 |
0.06 |
1.69% |
Date |
Firm |
Action |
From |
To |
2023-10-10 |
Morgan Stanley |
Upgrade |
Overweight |
Overweight |
2023-09-28 |
Raymond James |
Upgrade |
|
Outperform |
2023-07-27 |
Piper Sandler |
Upgrade |
Overweight |
Overweight |
2023-07-24 |
William Blair |
Upgrade |
|
Market Perform |
2023-07-13 |
HSBC |
Upgrade |
|
Buy |
2023-07-10 |
Morgan Stanley |
Upgrade |
Overweight |
Overweight |
Date |
Name |
Relation |
Quantity |
Description |
2024-02-28 |
BUCKBEE KEVIN K |
Officer |
6.98K |
Sale |
2024-03-19 |
DONOGHOE NICHOLAS |
Officer |
55.90K |
Sale |
2024-02-27 |
GONZALEZ RICHARD A |
Chief Executive Officer |
519.10K |
Sale |
2024-02-14 |
HUDSON THOMAS J |
Officer |
127.90K |
Stock Award(Grant) |
2024-02-28 |
MICHAEL ROBERT A. |
President |
98.65K |
Sale |
2024-02-22 |
REENTS SCOTT T. |
Chief Financial Officer |
15.43K |
Sale |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Group Inc |
159.30M |
21.46B |
9.03% |
2023-06-29 |
Blackrock Inc. |
139.16M |
18.75B |
7.88% |
2023-06-29 |
State Street Corporation |
78.18M |
10.53B |
4.43% |
2023-06-29 |
JP Morgan Chase & Company |
56.77M |
7.65B |
3.22% |
2023-06-29 |
Capital International Investors |
43.15M |
5.81B |
2.44% |
2023-06-29 |
Geode Capital Management, LLC |
34.95M |
4.71B |
1.98% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
55.03M |
7.41B |
3.12% |
2023-06-29 |
Vanguard 500 Index Fund |
42.01M |
5.66B |
2.38% |
2023-05-30 |
Fidelity 500 Index Fund |
19.79M |
2.73B |
1.12% |
2023-08-30 |
SPDR S&P 500 ETF Trust |
19.43M |
2.86B |
1.10% |
2023-09-29 |
American Mutual Fund Inc |
17.76M |
2.65B |
1.01% |
2023-08-30 |
iShares Core S&P 500 ETF |
16.50M |
2.43B |
0.93% |
Dividend |
Date |
1.55 |
2024-04-12 |
1.55 |
2024-01-15 |
1.55 |
2024-01-12 |
1.48 |
2023-10-12 |
1.48 |
2023-07-14 |
1.48 |
2023-07-13 |